Teva Releases Q2 2026 Aide Memoire
Teva (NYSE:TEVA) announced its Q2 2026 Aide Memoire is now available on the investors page of its website.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Teva (NYSE:TEVA) announced its Q2 2026 Aide Memoire is now available on the investors page of its website. The document compiles previously disclosed public information to help investors prepare for second quarter 2026 results, expected on July 29, 2026, at 7:00 a.m. ET, followed by an earnings conference call at 8:00 a.m. ET.
Details
News Market Reaction – TEVA
On Jun 22, the first trading day after this news, TEVA closed 2.29% above the previous close.
Data tracked by StockTitan Argus for the Jun 22 session.
Key Figures
- Q2 2026 results date
- July 29, 2026
- Earnings release scheduled at 7:00 a.m. ET with 8:00 a.m. ET call
- Net revenues
- $3,982 million
- Three months ended March 31, 2026
- Net revenues prior year
- $3,891 million
- Three months ended March 31, 2025
- Net income
- $369 million
- Three months ended March 31, 2026
- Diluted EPS
- $0.31
- Three months ended March 31, 2026
- Cash and cash equivalents
- $3,741 million
- As of March 31, 2026
- Senior notes and loans
- $14,015 million
- As of March 31, 2026
- Legal provisions
- $4,680 million
- Settlements and loss contingencies as of March 31, 2026
Historical Context
-
Closed Emalex Biosciences deal, adding late-stage Tourette syndrome asset to pipeline.
-
Long-term AUSTEDO data highlighted sustained tardive dyskinesia treatment benefits.
-
Real-world AUSTEDO data showed Huntington’s chorea and quality-of-life improvements.
-
Launched AHZANTIVE aflibercept biosimilar across several European markets.
-
Announced participation in Goldman Sachs Global Healthcare Conference fireside chat.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website.
Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of second quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the Aide Memoire document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Quarterly Report on Form 10-Q for the first quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.